权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Role of miRNAs in Vascular Physiology

miRNA 在血管生理学中的作用

基本信息

批准号：
8266380
负责人：
Akiko Hata
金额：
$ 38.24万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-06-01 至 2014-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8266380
关键词：
Adopted Aftercare Anabolism Angioplasty Apoptosis Arteries Atherosclerosis BMPR2 gene Biogenesis Blood Blood Vessels Bone Morphogenetic Proteins Cardiovascular Diseases Cell Nucleus Complex Consensus Data Development Disease Down-Regulation Etiology Exercise Exhibits Failure Family Gene Expression Gene Expression Regulation Gene Targeting Genes Germ-Line Mutation Goals Growth Factor Hypoxia Inherited Lung Lymphangioleiomyomatosis Maintenance Maps Mediating Messenger RNA MicroRNAs Microprocessor Molecular Mutation Pathogenesis Pathway interactions Patients Penetrance Phenotype Physiology Process Progressive Disease Proteins Pulmonary Vascular Resistance Pulmonary artery structure RNA Binding Regulation Right ventricular structure Role Signal Pathway Signal Transduction Smad Proteins Smad protein Smooth Muscle Myocytes Stenosis Structure Subgroup Transcript Transforming Growth Factors Translational Repression Transplantation Vascular Diseases Vascular Smooth Muscle Vascular remodeling Ventricular autosomal dominant trait bone morphogenetic protein 2 bone morphogenetic protein receptor type II mRNA Transcript Degradation member migration mortality novel pressure public health relevance pulmonary arterial hypertension receptor repaired response restenosis

项目摘要

DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is characterized by an increase in pulmonary vascular resistance that impedes ejection of blood by the right ventricle, leading to right ventricular failure. PAH is a serious condition for which there is no cure. Primary PAH is a rare but progressive disease with a mortality of 30 percent over 4 years. Recently germline mutations in bone morphogenetic protein receptor type II (BMPRII), a member of the transforming growth factor 2 (TGF2) receptor family, have been found in over 80 percent of familial PAH patients and in 30 percent of sporadic cases of PAH. The long-term objective of this application is to understand the molecular mechanism(s) by which BMPRII mutations contribute to the pathogenesis of PAH. The hypothesis of this application is that BMPR2 and its downstream signal are essential for maintenance of a normal pulmonary vascular structure and function. We have shown previously that the TGF2 family of growth factors, TGF2s and BMPs, promote a switch from a "synthetic" to "contractile" phenotype of pulmonary artery smooth muscle cells (PASMCs) by inducing the expression of VSMC-specific genes. We recently demonstrated that the expression of microRNA-21 (miR-21) is rapidly induced after a treatment with TGF2 or BMP in PASMCs. MiR-21 belongs to a family of short, noncoding, single-stranded RNAs (ssRNAs) called microRNAs (miRNAs) that regulate gene expression by targeting mRNAs in a sequence-specific manner, causing translational repression or mRNA degradation. Induction of miR-21 in PASMCs leads to downregulation of Programmed Cell Death 4 (PDCD4) which in turn leads to the elevation of VSMC-specific gene expression. Interestingly, our data indicate that TGF2 and BMP mediate miR-21 induction post- transcriptionally by promoting the processing of primary transcripts of miR-21 (pri-miR-21) into precursor miR- 21 (pre-miR-21) by the Drosha microprocessor complex in the nucleus. The main goal of this application is to investigate a mechanism of regulation of miR-21 biosynthesis by TGF2 and BMP, which is crucial for understanding a molecular mechanism of TGF2/BMP-mediated phenotype switch underlying the pathogenesis of PAH. To this end, SA1 will examine a mechanism of association of Smads with specific pri-miRNAs. SA2 will elucidate a role of Smad proteins in the TGF2/BMP-regulated pri-miR-21 processing. SA3 will explore a role of miR-21 target PDCD4 in the regulation of vascular smooth muscle phenotype. This application investigates the previously unexplored mechanism of gene regulation by the TGF2/BMP-Smad signaling pathway which is fundamental for understanding the pathogenesis and development of novel therapies for PAH. PUBLIC HEALTH RELEVANCE: Vascular smooth muscle cells (VSMC) are characterized in part by their ability to modulate their phenotype between a quiescent, differentiated "contractile" state and a proliferative, less differentiated, "synthetic" state; further, upon vascular damage, VSMCs adopt the synthetic phenotype as part of a normal repair process. It is suggested that the phenotypic modulation of VSMCs contributes to various disorders in the pulmonary and systemic arteries, including post-angioplasty re-stenosis, transplant vasculopathy, atherosclerosis, lymphangioleiomyomatosis, and pulmonary arterial hypertension (PAH). This application will elucidate a novel mechanism of regulation of VSMC phenotype in normal physiology, which is of fundamental importance in understanding the etiology of cardiovascular disorders.

描述（由申请人提供）：肺动脉高压（PAH）的特征是肺血管阻力增加，阻碍右心室的射血，导致右心室衰竭。多环芳烃是一种无法治愈的严重疾病。原发性多环芳烃是一种罕见的进行性疾病，4年内死亡率为30%。骨形态发生蛋白受体II型（BMPRII）是转化生长因子2 （TGF2）受体家族的一员，最近在超过80%的家族性PAH患者和30%的散发性PAH病例中发现了种系突变。这项应用的长期目标是了解BMPRII突变导致PAH发病的分子机制。本应用的假设是BMPR2及其下游信号对于维持正常的肺血管结构和功能至关重要。我们之前已经证明，TGF2家族的生长因子，TGF2s和bmp，通过诱导vsmc特异性基因的表达，促进肺动脉平滑肌细胞（PASMCs）从“合成”到“收缩”表型的转换。我们最近证明，在PASMCs中，TGF2或BMP处理后，microRNA-21 （miR-21）的表达被迅速诱导。MiR-21属于短链非编码单链rna （ssRNAs）家族，称为microRNAs (miRNAs)，其通过序列特异性靶向mRNA来调节基因表达，导致翻译抑制或mRNA降解。在PASMCs中诱导miR-21导致程序性细胞死亡4 （PDCD4）的下调，进而导致vsmc特异性基因表达的升高。有趣的是，我们的数据表明，TGF2和BMP通过促进细胞核中Drosha微处理器复合物将miR-21的初级转录本（pri-miR-21）加工成前体miR-21 (pre-miR-21)，从而介导miR-21的转录后诱导。本应用的主要目的是研究TGF2和BMP调控miR-21生物合成的机制，这对于理解TGF2/BMP介导的表型转换在多环芳烃发病机制中的分子机制至关重要。为此，SA1将研究Smads与特定pri- mirna的关联机制。SA2将阐明Smad蛋白在TGF2/ bmp调控的pri-miR-21加工中的作用。SA3将探讨miR-21靶点PDCD4在血管平滑肌表型调节中的作用。该应用研究了TGF2/BMP-Smad信号通路先前未被探索的基因调控机制，这是了解PAH发病机制和开发新疗法的基础。